PD-0325901

PD-0325901

Contact us: [email protected]

PD-0325901
1643-5
EUR 444

EZSolution? PD-0325901, Sterile-Filtered
1990-1
EUR 326.4

PD-1/PD-L1 Inhibitor 2
B1050-25
EUR 679.2

PD-1/PD-L1 Inhibitor 2
B1050-5
EUR 242.4

PD-1/PD-L1 Inhibitor 1
B1213-25
EUR 679.2

PD-1/PD-L1 inhibitor 2
B6023-25 25 mg
EUR 525.6
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

PD-1/PD-L1 inhibitor 2
B6023-5 5 mg
EUR 205.2
Description: PD-1/PD-L1 inhibitor 2 is a PD-1/PD-L1 interaction inhibitor.

PD-1/PD-L1 inhibitor 1
B6172-25 25 mg
EUR 543.6
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

PD-1/PD-L1 inhibitor 1
B6172-5 5 mg
EUR 201.6
Description: IC50: 0.006-0.10 ?MPD-1/PD-L1 inhibitor 1 is a PD-1/PD-L1 interaction inhibitor.Plenty of studies show that blocking the PD-1/PD-Ll interactions can lead to the restorage and augment of T cell activation in many systems.

PD 180970
A8606-10 10 mg
EUR 517.2
Description: ATP-competitive inhibitor of p210bcr/abl tyrosine kinase; selectively induces apoptosis in chronic myeloid leukemia (CML) K562 cells. Inhibits in vivo tyrosine phosphorylation of Gab2, CrkL and p210bcr/abl (IC50 values are 80, 80 and 170 nM respectively).

PD 169316
A8689-10 10 mg
EUR 195.6
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4.

PD 169316
A8689-5.1 10 mM (in 1mL DMSO)
EUR 268.8
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4.

PD 169316
A8689-50 50 mg
EUR 595.2
Description: IC50: A potent, selective and cell-permeable suppressor of p38 MAP kinase, with the IC50 value of 89 nM.PD169316, a specific p38 MAPK inhibitor, blocks signal transduction mediated by both TGF-? and Activin A, but not bone morphogenetic protein (BMP) 4.

PD 145305
C5830-10 10 mg
EUR 513.6
Description: PD 145305 is an inactive analog of PD 150606, a potent and selective calpains inhibitor [1]. Calpain is a class of cytosolic cysteine protease that is activated by elevated intracellular calcium.

PD 145305
C5830-5 5 mg
EUR 315.6
Description: PD 145305 is an inactive analog of PD 150606, a potent and selective calpains inhibitor [1]. Calpain is a class of cytosolic cysteine protease that is activated by elevated intracellular calcium.

PD 0332991
E1KS1116 5mg
EUR 812.4

PD 184161
C4361-10 10 mg
EUR 339.6
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions.

PD 184161
C4361-25 25 mg
EUR 673.2
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions.

PD 184161
C4361-5 5 mg
EUR 217.2
Description: IC50: 10-100 nMPD 184161 is a MEK1/2 inhibitor. The intracellular signaling pathway of mitogen-activated protein kinases is involved in the regulation of various cellular functions.

PD 166326
C3677-1 1 mg
EUR 193.2
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones.

PD 166326
C3677-10 10 mg
EUR 1128
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones.

PD 166326
C3677-5 5 mg
EUR 661.2
Description: IC50: 8 nM for c-abl PD 166326 is a receptor tyrosine kinase inhibitor.Receptor tyrosine kinases are the high-affinity cell surface receptors for many growth factors, cytokines, as well as hormones.

PD 150,606
1906-25
EUR 444

PD 150,606
1906-5
EUR 164.4

PD 98059
1666-5
EUR 189.6

PD 173074
1675-1
EUR 164.4

PD 173074
1675-100 Ask for price

PD 150606
A4413-25 25 mg
EUR 513.6
Description: PD 150606 is a specific inhibitor of calpain with Ki value of 0.21 ?M and 0.37 ?M for mu- and m- calpains, respectively [1].

PD 150606
A4413-5 5 mg
EUR 172.8
Description: PD 150606 is a specific inhibitor of calpain with Ki value of 0.21 ?M and 0.37 ?M for mu- and m- calpains, respectively [1].

PD 166793
A4438-10 10 mg
EUR 290.4
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure.

PD 166793
A4438-25 25 mg
EUR 597.6
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure.

PD 166793
A4438-5 5 mg
EUR 224.4
Description: Broad spectrum MMP inhibitor. Displays high affinity for MMP-2, -3 and -13 (IC50 values are 4, 7 and 8 nM respectively) and exhibits > 750-fold selectivity over MMP-1, -7 and -9. Attenuates left ventricular remodelling and dysfunction in rat model of heart failure.

PD 173074
A8253-10 10 mg
EUR 129.6
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 173074
A8253-5.1 10 mM (in 1mL DMSO)
EUR 142.8
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 173074
A8253-50 50 mg
EUR 254.4
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD 173074
A8253-S Evaluation Sample
EUR 97.2
Description: PD173074 is a poten and selective fibroblast growth factor receptor (FGFR) inhibitor. Fibroblast growth factor-2 is reported to be able to induce proliferation and chemoresistance in Small cell lung cancer (SCLC) cells.

PD-146176
B2313-25
EUR 810

PD-146176
B2313-5
EUR 248.4

PD-168393
B2352-25
EUR 496.8

PD-168393
B2352-5
EUR 170.4

PD 151746
B4791-100 100 mg
EUR 714
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 151746
B4791-25 25 mg
EUR 338.4
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 151746
B4791-5 5 mg
EUR 142.8
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 151746
B4791-5.1 10 mM (in 1mL DMSO)
EUR 151.2
Description: PD 151746 is a potent and selective inhibitor of calpain with Ki value of 0.26 ?M for ?-Calpain. Calpain is a calcium-dependent, non-lysosomal cysteine protease that expressed in mammals and many other organisms.

PD 334581
B5727-10 10 mg
EUR 583.2

PD 334581
B5727-50 50 mg
EUR 2220

PD 81723
B6705-10 10 mg
EUR 340.8

PD 81723
B6705-50 50 mg
EUR 1245.6

PD 102807
B6821-10 10 mg
EUR 466.8

PD 102807
B6821-50 50 mg
EUR 1771.2

PD 160170
B6972-10 10 mg
EUR 408

PD 169316
B1703-25
EUR 652.8

PD 169316
B1703-5
EUR 210

PD-166866
B2223-25
EUR 810

PD-166866
B2223-5
EUR 248.4

PD 176252
B7122-10 10 mg
EUR 614.4

PD 198306
B7124-1 1 mg
EUR 151.2
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

PD 198306
B7124-10 10 mg
EUR 634.8
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

PD 198306
B7124-5 5 mg
EUR 381.6
Description: IC50: 8 nM for MEK [1]PD 198306 is a potent, selective and non-ATP competitive MAPK/ERK-kinase (MEK) inhibitor. MEK is a kinase enzyme which phosphorylates mitogen-activated protein kinase (MAPK).

PD 135158
B7127-10 10 mg
EUR 583.2

PD 135158
B7127-50 50 mg
EUR 2220

PD 158780
B7130-10 10 mg
EUR 278.4

PD 158780
B7130-25 25 mg
EUR 543.6

PD 158780
B7130-5 5 mg
EUR 181.2

PD 118057
B7203-10 10 mg
EUR 400.8

PD 118057
B7203-50 50 mg
EUR 1491.6

PD 146176
B7208-10 10 mg
EUR 180

PD 146176
B7208-25 25 mg
EUR 344.4

PD 146176
B7208-50 50 mg
EUR 567.6

PD 173212
B7424-10 10 mg
EUR 634.8

PD 173212
B7424-5 5 mg
EUR 451.2

PD 173212
B7424-5.1 10 mM (in 1mL DMSO)
EUR 574.8

PD 161570
B7486-10 10 mg
EUR 544.8

PD 161570
B7486-50 50 mg
EUR 2056.8

PD 98,059
GK2140-10MG 10 mg
EUR 206.4

PD 98,059
GK2140-1MG 1 mg
EUR 109.2

PD 98,059
GK2140-50MG 50 mg
EUR 453.6

PD 98,059
GK2140-5MG 5 mg
EUR 164.4

PD 150,606
GL2543-25MG 25 mg
EUR 495.6

PD 150,606
GL2543-5MG 5 mg
EUR 184.8

PD-159020
HY-101598 1mg
EUR 1350

PD 123319
HY-10259 5mg
EUR 218.4

PD 169316
HY-10578 10mM/1mL
EUR 306

PD 90780
HY-110166 5mg
EUR 391.2

PD 407824
HY-18961 100mg
EUR 1850.4

PD 151746
HY-19749 50mg
EUR 589.2

PD-ECGF
GT15181 100 ug
EUR 631.2

PD 117519
HY-100032 5mg
EUR 142.8

PD-166866
HY-101296 10mM/1mL
EUR 165.6

PD-ECGF
PR15044 10 ug
EUR 584.4

Ribosome-inactivating protein PD-L1/PD-L2 Antibody
1-CSB-PA306294LA01PJJ
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Unconjugated. Tested in the following application: ELISA

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody
20-abx319445
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Anti-PD-L1
DB-241-0.1 100 μl
EUR 469.2
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1
DB-241-0.2 200 μl
EUR 675.6
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1
DB-241-0.5 500 μl
EUR 889.2
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1
DB-241-1 1 ml
EUR 1450.8
Description: rabbit monospecific clonal antibodies for ihc-p application; concentrated

Anti-PD-L1
DB-241-RTU-15 15 ml
EUR 813.6
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Anti-PD-L1
DB-241-RTU-7 7 ml
EUR 519.6
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Anti-PD-L1
DB241-RTU-15 15 ml
EUR 813.6
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

Anti-PD-L1
DB241-RTU-7 7 ml
EUR 519.6
Description: rabbit monospecific clonal antibodies for ihc-p application; prediluted (ready to use)

PD-L1 Antibody
49251-100ul 100ul
EUR 399.6

PD-L1 Antibody
49251-50ul 50ul
EUR 286.8

PD-L1 Peptide
46-156P 0.1 mg
EUR 405.6
Description: CD274 / PD-L1 Peptide

PD-L1 Antibody
4059-002mg 0.02 mg
EUR 206.18
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Antibody
4059-01mg 0.1 mg
EUR 523.7
Description: PD-L1 plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/CD279, PD-L1 modulates the activation threshold of T-cells and limits T-cell effector response (1). The PDCD1/CD279-mediated inhibitory pathway is exploited by tumors to attenuate anti-tumor immunity and facilitate tumor survival (2,3). Through a yet unknown activating receptor, it may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (4).

PD-L1 Peptide
4059P 0.05 mg
EUR 197.7
Description: (IN) PD-L1 peptide

PD-L2 Antibody
4063-002mg 0.02 mg
EUR 206.18
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.

PD-L2 Antibody
4063-01mg 0.1 mg
EUR 523.7
Description: PD-L2 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by co gnate peptides bound to MHC molecules on antigen-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PD-L1 and PD-L2, both of which are thought act as a negative regulator of T cell activation. However, it has been suggested that PD-L2 can act to stimulate an immunogenic response through and alternative receptor from PD-1.

PD-L2 Peptide
4063P 0.05 mg
EUR 197.7
Description: (IN) PD-L2 peptide

PD-1 Antibody
4065-002mg 0.02 mg
EUR 206.18
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Antibody
4065-01mg 0.1 mg
EUR 523.7
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Peptide
4065P 0.05 mg
EUR 197.7
Description: (CT) PD-1 peptide

PD-1 Antibody
4067-002mg 0.02 mg
EUR 206.18
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Antibody
4067-01mg 0.1 mg
EUR 523.7
Description: PD-1 Antibody: Cell-mediated immune responses are initiated by T lymphocytes that are themselves stimulated by cognate peptides bound to MHC molecules on antig en-presenting cells (APC). T-cell activation is generally self-limited as activated T cells express receptors such as PD-1 (also known as PDCD-1) that mediate inhibitory signals from the APC. PD-1 can bind two different but related ligands, PDL-1 and PDL-2. Upon binding to either of these ligands, signals generated by PD-1 inhibit the activation of the immune response in the absence of "danger signals" such as LPS or other molecules associated with bacteria or other pathogens. Evidence for this is seen in PD1-null mice who exhibit hyperactivated immune systems and autoimmune diseases.

PD-1 Peptide
4067P 0.05 mg
EUR 197.7
Description: (IN) PD-1 peptide

PD-1 Antibody
24505-100ul 100ul
EUR 468

PD-1 Antibody
24506-100ul 100ul
EUR 468

EZSolution? PD 98059
1783-5
EUR 189.6

PD 153035 Hydrochloride
1656-2
EUR 189.6

PD 123319 ditrifluoroacetate
A3704-10 10 mg
EUR 250.8
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 123319 ditrifluoroacetate
A3704-25 25 mg
EUR 489.6
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 123319 ditrifluoroacetate
A3704-5 5 mg
EUR 205.2
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD 123319 ditrifluoroacetate
A3704-50 50 mg
EUR 787.2
Description: Description:IC50 Value: 1.2 ±0.4 mM (Inhibition of adenylyl cyclase elicited by 0.1 microM Ang II) [2]PD 123319 ditrifluoroacetate is a potent, selective, non-peptide angiotensin AT2 receptor antagonist.

PD-L1 Protein
20-abx261703
  • EUR 4101.60
  • EUR 393.60
  • EUR 276.00
  • 1 mg
  • 20 ug
  • 5 ug

PD-L1 Protein
20-abx263458
  • EUR 1930.80
  • EUR 393.60
  • EUR 276.00
  • 100 ug
  • 10 ug
  • 2 µg

PD-ECGF Antibody
abx236264-100ug 100 ug
EUR 661.2

PD-0332991 isethionate
9480-25
EUR 652.8

PD-0332991 isethionate
9480-5
EUR 210

PD-123319 ditrifluoroacetate
9640-25
EUR 757.2

PD-123319 ditrifluoroacetate
9640-5
EUR 235.2

PD 98059, >99%
BC064-010 10mg
EUR 278.4

PD 98059, >99%
BC064-025 25mg
EUR 360

PD 98059, >99%
BC064-050 50mg
EUR 537.6

PD 168077 maleate
B6578-10 10 mg
EUR 362.4

PD 168077 maleate
B6578-50 50 mg
EUR 1315.2

PD-166285 dihydrochloride
B2094-25
EUR 757.2

PD-166285 dihydrochloride
B2094-5
EUR 235.2

PD 144418 oxalate
B7125-10 10 mg
EUR 408

PD 144418 oxalate
B7125-50 50 mg
EUR 1531.2

PD 168568 dihydrochloride
B7420-10 10 mg
EUR 369.6

PD 168568 dihydrochloride
B7420-50 50 mg
EUR 1363.2

PD 0332991 (Palbociclib)
B7798-25 25 mg
EUR 184.8
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6.

PD 0332991 (Palbociclib)
B7798-5 5 mg
EUR 129.6
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6.

PD 0332991 (Palbociclib)
B7798-S Evaluation Sample
EUR 97.2
Description: PD-0332991 is selective and oral inhibitor of cyclin-dependent kinase 4/6 with IC50 values of 11nM and 16nM, respectively for CDK4 and CDK6 [1].PD-0332991 is a highly specific inhibitor of CDK4/6.

PD-1 Antibody
P1001-01m 0.1m
EUR 198

PD-1 Antibody
P1001-1ml 1ml
EUR 451.2

PD-L1 Antibody
P1013-01m 0.1m
EUR 224.4

PD-L1 Antibody
P1013-1ml 1ml
EUR 807.6

PD-1,CD279
E6TA00107 0.1mg
EUR 411.6

PD-L1, CD274
E6TA00108 0.1mg
EUR 411.6

PD 123319 (ditrifluoroacetate)
HY-10259A 10mg
EUR 258

(+)-PD 128907 hydrochloride
HY-110000 50mg
EUR 901.2

PD-168077 maleate
HY-21098A 10mM/1mL
EUR 211.2

Phytolacca dioica Ribosome-inactivating protein PD-L1/PD-L2
1-CSB-EP306294PJJ
  • EUR 733.20
  • EUR 370.80
  • EUR 2192.40
  • EUR 1126.80
  • EUR 1461.60
  • EUR 476.40
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Phytolacca dioica Ribosome-inactivating protein PD-L1/PD-L2 expressed in E.coli

Ribosome-Inactivating Protein PD-L1/PD-L2 Polyclonal Antibody
A64216 100 µg
EUR 684.66
Description: The best epigenetics products

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (HRP)
20-abx319446
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (FITC)
20-abx319447
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ribosome-inactivating protein PD-L1 / PD-L2 Antibody (Biotin)
20-abx319448
  • EUR 493.20
  • EUR 2214.00
  • EUR 718.80
  • EUR 218.40
  • EUR 360.00
  • 100 ug
  • 1 mg
  • 200 ug
  • 20 ug
  • 50 ug

Ribosome-inactivating protein PD-L1/PD-L2 Antibody, HRP conjugated
1-CSB-PA306294LB01PJJ
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is HRP conjugated. Tested in the following application: ELISA

Ribosome-inactivating protein PD-L1/PD-L2 Antibody, FITC conjugated
1-CSB-PA306294LC01PJJ
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is FITC conjugated. Tested in the following application: ELISA

Ribosome-inactivating protein PD-L1/PD-L2 Antibody, Biotin conjugated
1-CSB-PA306294LD01PJJ
  • EUR 380.40
  • EUR 402.00
  • 100ug
  • 50ug
Description: A polyclonal antibody against Ribosome-inactivating protein PD-L1/PD-L2. Recognizes Ribosome-inactivating protein PD-L1/PD-L2 from Phytolacca dioica. This antibody is Biotin conjugated. Tested in the following application: ELISA

PD-ECGF Polyclonal Antibody
ABP53145-003ml 0.03ml
EUR 189.6
Description: A polyclonal antibody for detection of PD-ECGF from Human. This PD-ECGF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human PD-ECGF

PD-ECGF Polyclonal Antibody
ABP53145-01ml 0.1ml
EUR 346.8
Description: A polyclonal antibody for detection of PD-ECGF from Human. This PD-ECGF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human PD-ECGF

PD-ECGF Polyclonal Antibody
ABP53145-02ml 0.2ml
EUR 496.8
Description: A polyclonal antibody for detection of PD-ECGF from Human. This PD-ECGF antibody is for WB, IHC-P, ELISA. It is affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogenand is unconjugated. The antibody is produced in rabbit by using as an immunogen synthesized peptide derived from the N-terminal region of human PD-ECGF

PD-L1 Conjugated Antibody
C49251 100ul
EUR 476.4

PD-L1 (CD274) siRNA
20-abx910978
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

PD-L1 (CD274) siRNA
20-abx910979
  • EUR 661.20
  • EUR 878.40
  • 15 nmol
  • 30 nmol

anti- PD-ECGF antibody
FNab06264 100µg
EUR 702
Description: Antibody raised against PD-ECGF

PD-ECGF Polyclonal Antibody
ES4144-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against PD-ECGF from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

PD-ECGF Polyclonal Antibody
ES4144-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against PD-ECGF from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

PD-L2 Polyclonal Antibody
ES8685-100ul 100ul
EUR 334.8
Description: A Rabbit Polyclonal antibody against PD-L2 from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

PD-L2 Polyclonal Antibody
ES8685-50ul 50ul
EUR 248.4
Description: A Rabbit Polyclonal antibody against PD-L2 from Human. This antibody is tested and validated for WB, ELISA, IHC, WB, ELISA

PD-L1 Recombinant Protein
91-293 0.05 mg
EUR 405.6
Description: CD274, also known as B7-H1 or programmed death ligand 1 (PD-L1), is a 40 kD type I transmembrane protein and a member of the B7 family within the immunoglobulin receptor superfamily. Programmed death-1 ligand-1 (PD-L1, CD274, B7-H1) has been identified as the ligand for the immunoinhibitory receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. By binding to PD1 on activated T-cells and B-cells, PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly, it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.

PD-L2 Recombinant Protein
91-721 0.05 mg
EUR 821.4
Description: Programmed Cell Death 1 Ligand 2 (PDCD1LG2) is a member of the BTN/MOG family. PDCD1LG2 contains one Ig-like C2-type domain and one Ig-like V-type domain. PDCD1LG2 is highly expressed in the heart, placenta, pancreas, lung and liver; it is weakly expressed in the spleen, lymph nodes, and thymus. PDCD1LG2 is involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. PDCD1LG2 interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.

PD-L1 Recombinant Protein
92-486 0.05 mg
EUR 374.1
Description: Mouse Programmed cell death 1 ligand 1(Cd274，PD-L1), is a member of the growing B7 family of immune proteins.It involved in the costimulatory signal essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.B7-H1 has been identified as one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. B7-H1 is constitutively expressed in several organs such as heart, skeletal muscle B7-H1 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. The costimulatory function of B7-H1 is critical for enhancing maturation and differentiation of T-cells in lymphoid organs.B7-H1 expression is also induced in dendritic cells and keratinocytes after IFN gamma stimulation. Interaction of B7-H1 with PD1 results in inhibition of TCR-mediated proliferation and cytokine production. The B7-H1:PD1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance.

PD-L1 Recombinant Protein
92-487 0.05 mg
EUR 374.1
Description: Mouse Programmed cell death 1 ligand 1(Cd274，PD-L1), is a member of the growing B7 family of immune proteins.It involved in the costimulatory signal essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production.B7-H1 has been identified as one of two ligands for programmed death1 (PD1), a member of the CD28 family of immunoreceptors. B7-H1 is constitutively expressed in several organs such as heart, skeletal muscle B7-H1 expression is upregulated in a small fraction of activated T and B cells and a much larger fraction of activated monocytes. The costimulatory function of B7-H1 is critical for enhancing maturation and differentiation of T-cells in lymphoid organs.B7-H1 expression is also induced in dendritic cells and keratinocytes after IFN gamma stimulation. Interaction of B7-H1 with PD1 results in inhibition of TCR-mediated proliferation and cytokine production. The B7-H1:PD1 pathway is involved in the negative regulation of some immune responses and may play an important role in the regulation of peripheral tolerance.

PD-L2 Recombinant Protein
92-497 0.05 mg
EUR 437.1
Description: Programmed cell death 1 ligand 2 (PD-L2), also known as butyrophilin B7-DC or PDCD1 ligand 2, belongs to the member of B7 family which can regulate the activation and tolerance of T cells. PD-L2 is one ligand for Programmed cell death 1(PD-1), and the other is PD-L1. These two ligands shares 34% aa sequence identity. Mouse PD-L2 gene encodes a 273 amino acids (aa) protein with a putative 19 aa signal peptide, a 201 aa extracellular region , a 21 aa transmembrane domain and a 32 aa cytoplasmic region. The mouse PD-L2 gene is highly expressed in heart, placenta, pancreas, lung and liver while expressed weakly in spleen, lymph nodes and thymus. Besides, the expression of PD-L2 gene can be induced on dendritic cells grown from peripheral blood mononuclear cells under CSF2 and IL4/interleukin-4 treatment, and up-regulated by IFNG/IFN-gamma stimulation in monocytes. PD-L2 usually functions in a PDCD1-independent manner and is involved in regulating costimulatory signal which is essential for T-cell proliferation and IFNG production. Recent studies demonstrate that the expression of PD-L2 on the tumor cells promotes CD8 T cell–mediated rejection of tumor cells, at both the induction and effector phase of antitumor immunity. Moreover, PD-L2 binds to PD-1 cells and enhances T cell killing in a PD-1–independent mechanism.

PD-L1 Rabbit pAb
A11273-100ul 100 ul
EUR 369.6

PD-0325901